A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens

被引：0
|
作者：
Palmer, AJ
Roze, S
Valentine, WJ
Schmidt, I
Wittrup-Jensen, KW
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A288 / A288
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1 diabetes in the UK
    Lloyd, A.
    Townsend, C.
    Munro, V.
    Twena, N.
    Nielsen, S.
    Holman, A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (03) : 599 - 605
  • [32] Basal bolus therapy among type 1 diabetes patients: A comparative cost-effectiveness analysis of analog- and human-based insulin regimens
    Valentine, W
    Cobden, D
    Palmer, A
    Roze, S
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A35 - A35
  • [33] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
    Gunes, E.
    Gunes, M.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
  • [34] Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart
    Vague, P
    Selam, JL
    Skeie, S
    De Leeuw, I
    Elte, JWF
    Haahr, H
    Kristensen, A
    Draeger, E
    [J]. DIABETES CARE, 2003, 26 (03) : 590 - 596
  • [35] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal
    Silva, C.
    Alves, C.
    Negreiro, F.
    Fonseca, M. A.
    Aagren, M.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A227 - A227
  • [36] Safety and Effectiveness of Insulin Aspart in Basal-Bolus Regimens Regardless of Age: A1chieve Study Results
    Latif, Zafar A.
    Hussein, Zanariah
    Litwak, Leon
    El Naggar, Nabil
    Chen, Jian-Wen
    Soewondo, Pradana
    [J]. DIABETES THERAPY, 2013, 4 (01) : 103 - 118
  • [37] Safety and Effectiveness of Insulin Aspart in Basal-Bolus Regimens Regardless of Age: A1chieve Study Results
    Zafar A. Latif
    Zanariah Hussein
    Leon Litwak
    Nabil El Naggar
    Jian-Wen Chen
    Pradana Soewondo
    [J]. Diabetes Therapy, 2013, 4 : 103 - 118
  • [38] Comparison of insulin aspart, regular insulin, and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
    Arslanian, S
    Foster, C
    Wright, N
    Stender, S
    Hu, P
    Hale, P
    Hale, D
    [J]. DIABETES, 2005, 54 : A517 - A518
  • [39] Mealtime insulin aspart reduces the long-term cost of complications compared to human insulin as part of basal-bolus therapy in polish type 2 diabetes patients
    Goodall, G.
    Nielsen, S.
    Townsend, C.
    Kotchie, R.
    Erny-Albrecht, K.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A265 - A265
  • [40] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, used once daily in basal-bolus treatment with insulin aspart in type 1 diabetes
    Hirsch, I.
    Franek, E.
    Courreges, J. P.
    Mersebach, H.
    Dykiel, P.
    Bode, B. W.
    [J]. DIABETOLOGIA, 2011, 54 : S427 - S427
12345